Belimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.
Target
TNFSF13B/CD257
Research Area
Biosimilars
Clonality
Monoclonal
Reactivity
Human
Expression
Recombinant
Tested Applications
ELISA
Host
Human
Recommended dilutions
Optimal dilutions/concentrations should be determined by the end user.
Conjugation
Unconjugated
Isotype
IgG1 Lambda
Form
Liquid
Purity
> 95%
Purification
Purified from cell culture supernatants by Protein A/G chromatography.
Storage
Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life
12 months.
Buffer
0.01 M PBS, pH 7.4.
CAS Number
356547-88-1
Concentration
Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability
Shipped within 5-10 working days.
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
We use cookies necessary for the function of our website, to improve your experience, analyse our traffic, and cookies that optimise the performance. To learn more about our cookies, please read our Cookie Notice.